Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

312.95DKK
3:59pm BST
Change (% chg)

kr.2.95 (+0.95%)
Prev Close
kr.310.00
Open
kr.310.00
Day's High
kr.313.05
Day's Low
kr.308.05
Volume
1,790,724
Avg. Vol
2,779,136
52-wk High
kr.354.80
52-wk Low
kr.278.15

Latest Key Developments (Source: Significant Developments)

Novo Nordisk Says Oral Semaglutide Shows Superior Weight Loss, HbA1c Reduction In Pioneer 5 Trial
9:56am BST 

Aug 20 (Reuters) - NOVO NORDISK A/S SAYS::ORAL SEMAGLUTIDE PROVIDES SUPERIOR HBA1C AND WEIGHT REDUCTIONS VERSUS PLACEBO IN PEOPLE WITH TYPE 2 DIABETES AND RENAL IMPAIRMENT IN THE PIONEER 5 TRIAL.TRIAL ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL APPROACH BY DEMONSTRATING STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA(1C) WITH ORAL SEMAGLUTIDE COMPARED TO PLACEBO AT WEEK 26.PEOPLE TREATED WITH ORAL SEMAGLUTIDE ACHIEVED STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN BODY WEIGHT COMPARED TO PLACEBO AT WEEK 26.  Full Article

Novo Nordisk Initiated New Share Repurchase Programme Of Up To Dkk 2.4 Bln As Part Of 2018 Share Repurchase Programme
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK-AS PART OF UP TO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME,CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AMOUNT OF UP TO DKK 2.4 BILLION.  Full Article

Novo Nordisk Purchases B Shares Worth DKK 954 Mln From Novo Holdings Under 2018 Share Repurchase Programme
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 954 MILLION FROM NOVO HOLDINGS A/S UNDER 2018 SHARE REPURCHASE PROGRAMME.TRANSACTION PART OF CO'S 2018 SHARE REPURCHASE PROGRAMME OF UP TO TOTAL OF DKK 14 BILLION TO BE EXECUTED DURING 12-MONTH PERIOD STARTING 1 FEB.TRANSACTION IS IN LINE WITH ANNOUNCEMENT ON 8 AUGUST THAT NOVO HOLDINGS INTENDS TO MAINTAIN OWNERSHIP OF NOVO NORDISK'S SHARE CAPITAL AROUND 28%.  Full Article

Therachon Raises $60 Million Mezzanine Financing
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Therachon AG::THERACHON RAISES $60 MILLION MEZZANINE FINANCING TO ADVANCE LEAD PROGRAM IN ACHONDROPLASIA AND TO EXPAND RARE DISEASE PIPELINE.THERACHON AG SAYS FINANCING LED BY NOVO HOLDINGS, JOINED BY COWEN HEALTHCARE INVESTMENTS, PFIZER VENTURES, AMONG OTHERS.  Full Article

Vattenfall, Novozymes, Novo Nordisk Sign Power Purchase Agreement From Denmark's Largest Offshore Wind Park
Friday, 13 Jul 2018 

July 13 (Reuters) - VATTENFALL AB [RIC:RIC:VATN.UL]::VATTENFALL, NOVOZYMES AND NOVO NORDISK SIGN A LONG TERM POWER PURCHASE AGREEMENT FROM DENMARK'S LARGEST OFFSHORE WIND PARK, KRIEGERS FLAK.SAYS DEAL WILL COVER APPROXIMATELY A FIFTH OF FARM'S PRODUCTION.KRIEGERS FLAK IS SCHEDULED TO BE IN FULL OPERATION BY THE END OF 2021.THE DEAL ENTERS INTO FORCE FROM JANUARY 1 2020. BETWEEN THEN AND 2021 THE POWER WILL BE SOURCED FROM OTHER VATTENFALL WIND FARMS IN DENMARK.  Full Article

Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Novo Nordisk A/S ::ORAL SEMAGLUTIDE SHOWS STATISTICALLY SIGNIFICANTLY GREATER REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO VICTOZA AND SITAGLIPTIN IN PIONEER 4 AND 7 TRIALS.PIONEER 4 ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL APPROACH BY DEMONSTRATING A NON-INFERIOR REDUCTION IN HBA1C.ORAL SEMAGLUTIDE PROVIDED STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO PLACEBO..PLANS TO REPORT PIONEER 3 TRIAL COMPARING 3, 7 AND 14 MG ORAL SEMAGLUTIDE WITH 100 MG SITAGLIPTIN BEFORE END OF Q2 OF 2018.  Full Article

Novo Nordisk And Kallyope Collaborates To Discover New Obesity And Diabetes Drugs
Tuesday, 19 Jun 2018 

June 19 (Reuters) - NOVO NORDISK A/S ::SAYS KALLYOPE, INC AND NOVO NORDISK A/S TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A RESEARCH COLLABORATION AND OPTION AGREEMENT TO DISCOVER NOVEL PEPTIDE THERAPEUTICS TO TREAT OBESITY AND DIABETES.SAYS KALLYOPE WILL RECEIVE AN UPFRONT PAYMENT AND RESEARCH SUPPORT FOR ACTIVITIES CONDUCTED IN COLLABORATION.SAYS UNDER TERMS OF AGREEMENT, NOVO NORDISK HAS AN OPTION TO LICENSE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALISE UP TO SIX PRODUCTS DISCOVERED IN COLLABORATION.KALLYOPE WILL RECEIVE A LICENSE FEE IF NOVO NORDISK CHOOSES TO EXERCISE AN OPTION TO A THERAPEUTIC DISCOVERED AND VALIDATED IN THE JOINT RESEARCH PLAN AND POTENTIAL RESEARCH, DEVELOPMENT AND SALES MILESTONES.IN ADDITION, KALLYOPE WILL RECEIVE ROYALTIES ON WORLDWIDE PRODUCT SALES OF LICENSED PRODUCTS.  Full Article

Novo Nordisk Says Oral Semaglutide Shows Superior Improvement In HbA1c Vs Empagliflozin In Pioneer 2 Trial
Tuesday, 29 May 2018 

May 29 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK SAYS ORAL SEMAGLUTIDE SHOWS SUPERIOR IMPROVEMENT IN HBA1C VERSUS EMPAGLIFLOZIN IN PIONEER 2 TRIAL.NOVO NORDISK-TRIAL ACHIEVED PRIMARY OBJECTIVE DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN HBA(1C) WITH ORAL SEMAGLUTIDE COMPARED TO EMPAGLIFLOZIN.  Full Article

Epigen Biosciences Says Enters Collaboration Agreement With Novo Nordisk A/S
Wednesday, 23 May 2018 

May 23 (Reuters) - Novo Nordisk A/S ::EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION.EPIGEN BIOSCIENCES SAYS CO WILL ALSO BE ELIGIBLE TO GET TIERED ROYALTIES AND MILESTONES ON WORLDWIDE SALES OF PRODUCTS THAT ARISE FROM COLLABORATION.  Full Article

Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme
Friday, 4 May 2018 

May 4 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME.TODAY ENTERED INTO AN AGREEMENT TO PURCHASE 3,415,895 B SHARES OF A VALUE OF DKK 1,038 MILLION FROM NOVO HOLDINGS A/S.TRANSACTION PART OF CO'S 2018 SHARE REPURCHASE PROGRAMME OF UP TO DKK 14.0 BILLION TO BE EXECUTED DURING 12 MONTHS PERIOD FROM 1 FEBRUARY 2018.TRANSACTION IN LINE WITH ANNOUNCEMENT ON 2 MAY THAT NOVO HOLDINGS A/S INTENDS TO MAINTAIN ITS OWNERSHIP OF CO'S SHARE CAPITAL AROUND 28%.  Full Article

GLOBAL MARKETS-Oil drops on China import data, weighing on equities

NEW YORK, Aug 8 Oil prices slumped on Wednesday after Chinese import data showed a slowdown in demand and weighed on world equity markets, which traded near break-even as U.S. technology shares extended recent gains.